Dare Bioscience Inc. (1221)
XBER 
NASDAQ (CM) Primary XBER Summary
Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript
Daré Bioscience, Inc. ( DARE ) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns November 17, 2025 12:00 PM EST Company Participants Jennifer Kiang Sabrina Johnson - CEO, President, Principal Financial Officer, Secretary & Director Conference Call Participants Sheryl Kingsberg Jim Simon Presentation Jennifer Kiang All right. Good morning, everyone, and thanks so much for joining us today.
Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript
Daré Bioscience, Inc. ( DARE ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Johnson - CEO, President, Principal Financial Officer, Secretary & Director Conference Call Participants Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Presentation Operator Welcome to the conference call hosted by Daré Bioscience to review the company's third quarter 2025 financial results and to provide a business update. This call is being recorded.
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.55 per share a year ago.
Dare Bioscience Inc. (1221) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Dare Bioscience Inc. ever had a stock split?
Dare Bioscience Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sabrina Martucci Johnson CEO | XBER Exchange | US23666P2002 ISIN |
| US Country | 21 Employees | - Last Dividend | 1 Jul 2024 Last Split | 10 Apr 2014 IPO Date |
Overview
Daré Bioscience, Inc. is a forward-looking biopharmaceutical company based in San Diego, California, committed to the advancement of women's health. Through rigorous research and development, the company focuses on creating innovative therapeutic solutions across a wide spectrum of women's health issues. These areas include contraception, reproductive health, menopause support, fertility enhancement, and the treatment of sexual and vaginal health conditions. Daré Bioscience operates with a vision to identify, develop, and bring to market a diverse portfolio of pharmaceutical products designed to improve the health and wellbeing of women around the world.
Products and Services
- Ovaprene - A non-hormonal, monthly intravaginal contraceptive that offers a hormone-free alternative for women seeking birth control.
- Sildenafil Cream, 3.6% - Formulated for the treatment of female sexual arousal disorder, this cream represents an innovative approach to enhancing female sexual health.
- DARE-HRT1 - Designed to treat moderate to severe vasomotor symptoms associated with menopause, as part of a comprehensive menopausal hormone therapy plan.
- DARE-VVA1 - A treatment option for women experiencing moderate-to-severe dyspareunia, or pain during sexual intercourse, often a challenging condition for many women.
- DARE-CIN - Focuses on the treatment of cervical intraepithelial neoplasia and other human papillomavirus (HPV) related pathologies, offering a targeted approach to cervical health.
- DARE-PDM1 - Developed for the treatment of primary dysmenorrhea, providing relief for women suffering from painful menstrual cycles.
- DARE-204 and DARE-214 - Long-acting contraceptive options that provide coverage over 6-month and 12-month periods, respectively, offering extended protection against unwanted pregnancy.
- DARE-FRT1 - A treatment developed for luteal phase support as part of an in vitro fertilization (IVF) treatment plan, assisting women in their journey towards conception.
- DARE-PTB1 - Focused on the prevention of preterm birth, this innovative approach seeks to address a critical issue in neonatal care.
- DARE-LARC1 - A long-lasting contraceptive implant, providing women with a durable and convenient birth control option.
- DARE-LBT - Developed for vaginal health support, aligning with the company's commitment to comprehensive female healthcare.
- DARE-GML - Representing a multi-target antimicrobial agent, this product targets a range of infections, demonstrating the company's versatility in addressing women's health.
- DARE-RH1 - A novel approach to non-hormonal contraception for both men and women, targeting the CatSper ion channel for innovative birth control solutions.
- DARE-PTB2 - Focused on the prevention and treatment of idiopathic preterm birth through the inhibition of a stress response protein, showcasing the company’s commitment to advancing prenatal care.
- XACIATO - Approved for the treatment of bacterial vaginosis in female patients 12 years of age and older, enhancing Daré Bioscience’s portfolio in addressing common women's health conditions.
Contact Information
